Mallinckrodt PLC

Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes innovative specialty pharmaceutical brands. The Specialty Generics segment relates to niche specialty generic drugs and active pharmaceutical ingredients. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mallinckrodt Plc  on Tuesday said it had agreed to a $1.6 billion settlement proposal in which its generic drug business would file bankruptcy in order to resolve thousands of lawsuits alleging it helped fuel the U.S. opioid epidemic.

Mallinckrodt agrees to $1.6 bln opioid settlement, unit to seek bankruptcy

Investors are cheering the company's deal to settle opioid-related lawsuits.

Why Mallinckrodt Stock Is Soaring Today

Shares of generic pharma companies popped Tuesday after Mallinckrodt announced a $1.6 billion opioid settlement and Perrigo gained Food and Drug Administration approval for an inhaler.
The post Mallinckrodt Unveils $1.6 Billion Opioid Deal — And Generic Stocks Pop appeared first on Investor's Business Daily.

Mallinckrodt Unveils $1.6 Billion Opioid Deal — And Generic Stocks Pop

Mallinckrodt PLC (NYSE: MNK) shares are ripping higher Tuesday after the company announced a global opioid settlement agreement that limits its payout to $1.6 billion and it aslo reported better-than-expected fourth-quarter results.

Mallinckrodt Rips Higher After Company Confirms $1.6B Opioid Litigation Settlement

Mallinckrodt (MNK) delivered earnings and revenue surprises of 17.07% and 3.99%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Mallinckrodt (MNK) Surpasses Q4 Earnings and Revenue Estimates

Shares of Mallinckrodt PLC MNK, -18.55% soared 15% in premarket trading Tuesday, after plunging 19% the previous session, after the drug maker announced a settlement agreement that would resolve all opioid-related claims.

Mallinckrodt's stock bounces after opioid-related settlement deal, earnings that beat expectations

Shares fell by as much as 45% in light of the news.

Mallinckrodt Considers Bankruptcy Over Opioid Lawsuits

Mallinckrodt plc (NYSE: MNK) shares traded sharply lower on Monday afternoon following a report suggesting the company is in creditor talks ahead of a potential bankruptcy.

Mallinckrodt Plummets On Report Of Possible Generics Business Bankruptcy

Shares of Mallinckrodt PLC MNK, -40.43% plummeted 45.4% in afternoon trading, after The Wall Street Journal reported that the drugmaker, which has been embroiled in litigation over its role in the opioid crisis, has begun talks with creditors ahead of a potential bankruptcy of its U.S.

Mallinckrodt's stock suffering record selloff after WSJ report of talks with creditors

Mallinckrodt (MNK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Mallinckrodt (MNK) Might Surprise This Earnings Season?

Clovis Oncology

3D Systems

Fulgent Genetics

By Harry Boxer, TheTechTrader Here are three health stocks and one technology stock that are at or near key breakout points:

4 Stocks Looking Higher During Earnings Season

Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Mallinckrodt (MNK) Beat Estimates Again in Its Next Earnings Report?

Insys Therapeutics

Johnson & Johnson

McKesson

Bankruptcies reached a new high not seen since 2011, with opioid lawsuits playing a big role.

Biotech Bankruptcies Hit New Record in 2019

Mallinckrodt (MNK) stock may be a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Consider Mallinckrodt (MNK) Stock?

Endo International

SmileDirectClub

These stocks skyrocketed during healthcare's biggest event of the year -- the J.P. Morgan Healthcare Conference.

3 Big Winners From the "Super Bowl of Healthcare"

Momentum from its CEO's comments earlier this week continues.

Why Mallinckrodt Stock Is Jumping Today

Shares of Mallinckrodt PLC MNK, +21.79% shot up 22% in afternoon trading Wednesday, enough to pace the NYSE's gainers, to stretch its gains for the week to 38%.

Mallinckrodt's stocks soars on heavy volume toward near-40% gain this week after comments at broker conference

Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.

Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock?

Mallinckrodt (MNK) Up 28.5% Since Last Earnings Report: Can It Continue?

AmerisourceBergen

Amneal Pharmaceuticals

Teva Pharmaceutical

Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.

Fed Reportedly Opens Criminal Investigation on Opioid Makers

Pharmaceutical companies are in trouble over their role in fueling the opioid crisis facing the U.S.

Pharma Companies Shares Tank As Feds Investigate Opioid Crisis

Federal prosecutors have opened a criminal investigation into whether pharmaceutical companies intentionally allowed opioid painkillers to flood communities, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Federal prosecutors open criminal probe of opioid makers, distributors: WSJ

Cardinal Health

Shares of the companies embroiled in opioid litigation fell in afternoon trading afterThe Wall Street Journal reported the federal government had opened a criminal investigation into some opioid makers and distributors, citing sources.

Shares of opioid makers and distributors drop on criminal probe

Mylan

Shares of generic drugmakers are up in morning trading, with Mallinckrodt  leading the pack as its stock rallied 15%. Teva Pharmaceutical Industries Ltd.

Shares of generic drugmakers jump in morning trading

Mallinckrodt (MNK) misses on sales but beats on earnings in the third quarter of 2019.

News for Mallinckrodt PLC Stock (MNK)